Three abstracts on our investigational gene therapy candidates have been accepted for presentation at the ARVO 2025 Meeting, to take place from May 4 to 8, 2025 in Salt Lake City, UT. These include a presentation on 12-month data from the first three adult patients in the ongoing Phase 1/2 trial of OPGx-LCA5. Data on the first pediatric patient in the trial for OPGx-LCA5 data are anticipated in the third quarter of 2025. Initiation of a Phase 1b/2a clinical trial for OPGx-BEST1 is planned for 2025. We aim to obtain preliminary data by the first quarter of 2026. Topline date from the LYNX-2 pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for decreased vision under low light conditions following keratorefractive surgery are expected mid-year 2025. Topline data from the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia are expected in the first half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics presents data on phentolamine ophthalmic solution 0.75%
- Opus Genetics prices 21.05M shares at 95c in public offering
- Opus Genetics announces presentations at ARVO 2025 meeting
- Opus Genetics gets Fast Track designation for phentolamine ophthalmic solution
- Opus Genetics provides update on OPGx-LCA5 clinical program